Gland Pharma

Nov 14, 2017

Novartis ventures itself into developing new editing technology Novartis has moved beyond CRISPR and CAR-T gene editing technology with its latest deal with Homology Medicines, aiming to improve upon its R&D work in the arena of cell and gene therapy. The deal involves Novartis using the gene editing technology ...

Sep 20, 2017

Chinese pharma company Shanghai Fosun to acquire 74% stake in Indian company Gland Pharma for $1.09 billion In July last year Chinese company Shanghai Fosun Pharmaceutical announced to acquire 74% per cent stake in Gland Pharma (Hyderabad-based Company) for not more than USD 1.09 billion. Initially the deal was set...